CY1122871T1 - Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 - Google Patents

Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1

Info

Publication number
CY1122871T1
CY1122871T1 CY20201100236T CY201100236T CY1122871T1 CY 1122871 T1 CY1122871 T1 CY 1122871T1 CY 20201100236 T CY20201100236 T CY 20201100236T CY 201100236 T CY201100236 T CY 201100236T CY 1122871 T1 CY1122871 T1 CY 1122871T1
Authority
CY
Cyprus
Prior art keywords
expression
ctcs
primary
immunotherapy
patients
Prior art date
Application number
CY20201100236T
Other languages
English (en)
Inventor
Evrykleia LIANIDOU
Areti STRATI
Original Assignee
Pharmassist Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmassist Ltd filed Critical Pharmassist Ltd
Publication of CY1122871T1 publication Critical patent/CY1122871T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Liquid Crystal Substances (AREA)
  • Auxiliary Devices For And Details Of Packaging Control (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια εξαιρετικά ευαίσθητη, ειδική και αναπαραγώγιμη μέθοδο (RΤ-qΡCR) ποσοτικού προσδιορισμού της έκφρασης της PD-L1 σε πραγματικό χρόνο σε ένα δείγμα RΝΑ, όπου το RΝΑ έχει απομονωθεί από κυκλοφορούντα καρκινικά κύτταρα (Circulating Tumor Cells, CTCs) περιφερικού αίματος ασθενών με καρκίνο ή φρέσκους ιστούς πρωτοπαθούς όγκου. Πιο συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με μια μέθοδο για την ανίχνευση των PD-L1 mRNA θετικών CTCs ή πρωτοπαθών ιστών (fresh frozen), βασιζόμενη στον ποσοτικό προσδιορισμό του μοριακού βιοδείκτη (PD-L1) σε δείγματα ασθενών με καρκίνο. Επιπλέον, η χρήση της μεθόδου σύμφωνα με την εφεύρεση, μπορεί να γίνει πριν, κατά την διάρκεια και μετά την ανοσοθεραπεία ή κάθε άλλη θεραπεία παρέχοντας σημαντικές πληροφορίες σχετικά με την στρατολόγηση ή την παρακολούθηση των ασθενών στην αποτελεσματικότητα των anti-PD-L1 αναστολέων. Αυτή η μέθοδος μπορεί να αποτελέσει ένα συνοδό διαγνωστικό τεστ (companion diagnostic test) προκειμένου να εκτιμηθεί η υπερ-έκφραση της ΡD-L1 στα CTCs ή σε πρωτοπαθείς όγκους, παρέχοντας κλινικές εφαρμογές που θα μπορούν να έχουν ένα σημαντικό αποτέλεσμα στις θεραπευτικές παρεμβάσεις, αφού η έκφραση της ΡD-L1 σχετίζεται με την ανταπόκριση στην ανοσοθεραπεία.
CY20201100236T 2015-10-27 2020-03-16 Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 CY1122871T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GR2015/000054 WO2017072539A1 (en) 2015-10-27 2015-10-27 Method for the quantification of pd-l1 expression

Publications (1)

Publication Number Publication Date
CY1122871T1 true CY1122871T1 (el) 2021-05-05

Family

ID=54548209

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100236T CY1122871T1 (el) 2015-10-27 2020-03-16 Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1

Country Status (13)

Country Link
US (2) US20190085401A1 (el)
EP (1) EP3368683B1 (el)
CY (1) CY1122871T1 (el)
DK (1) DK3368683T3 (el)
ES (1) ES2779309T3 (el)
HR (1) HRP20200487T1 (el)
HU (1) HUE048265T2 (el)
LT (1) LT3368683T (el)
PL (1) PL3368683T3 (el)
PT (1) PT3368683T (el)
RS (1) RS60075B1 (el)
SI (1) SI3368683T1 (el)
WO (1) WO2017072539A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018048936A1 (en) 2016-09-06 2018-03-15 Incelldx, Inc. Methods of detecting per cell pd-l1 expression and uses thereof
US11726089B2 (en) 2016-09-06 2023-08-15 Incelldx, Inc. Methods of assaying neoplastic and neoplasia-related cells and uses thereof
CN107460239A (zh) * 2017-07-23 2017-12-12 嘉兴允英医学检验有限公司 一种用于pd‑l1表达水平检测的试剂盒
EP3697927B1 (en) * 2017-10-19 2022-12-14 Bio-Rad Laboratories, Inc. Digital amplification assays with unconventional and/or inverse changes in photoluminescence
CN108507992A (zh) * 2018-04-09 2018-09-07 苏州大学附属第医院 循环肿瘤细胞表面标志分子pd-l1的检测方法
CA3109216A1 (en) * 2018-08-16 2020-02-20 Musc Foundation For Research Development Recombinant myxoma viruses and uses thereof
WO2020092589A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Immune checkpoint therapeutic methods
CN109628596A (zh) * 2019-01-18 2019-04-16 臻悦生物科技江苏有限公司 Rna水平检测pd-1和pd-l1表达量的试剂盒及方法
CN109576350B (zh) * 2019-01-18 2021-01-29 深圳恒特基因有限公司 一种dna与rna同时定量的试剂盒、方法及质控方法
WO2020214606A1 (en) * 2019-04-15 2020-10-22 The Medical College Of Wisconsin, Inc. Recombinant pd-l1 peptides and methods of use
CN114902048A (zh) * 2020-02-18 2022-08-12 创新生物有限公司 伴随诊断用生物标志物组合物及包含其的伴随诊断用试剂盒
CN111521796A (zh) * 2020-04-21 2020-08-11 山东第一医科大学(山东省医学科学院) 一种检测肾癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法
WO2022040350A1 (en) * 2020-08-19 2022-02-24 Ohio State Innovation Foundation Highly sensitive platform to characterize extracellular vesicular biomarkers for cancer immunotherapy
CN112462072B (zh) * 2020-09-24 2022-06-03 浙江大学 一种tmub1蛋白在制备肿瘤免疫抑制分子检测剂中的应用
CN112725418A (zh) * 2021-01-25 2021-04-30 深圳乐土生物科技有限公司 基于游离rna检测pd-l1表达量的方法及其试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797813B2 (en) * 1996-09-23 2004-09-28 Schering Corporation AK155 antibodies and binding fragments thereof
KR20230070054A (ko) * 2013-03-15 2023-05-19 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
EP3189080A1 (en) * 2014-09-05 2017-07-12 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)

Also Published As

Publication number Publication date
EP3368683A1 (en) 2018-09-05
LT3368683T (lt) 2020-04-10
ES2779309T3 (es) 2020-08-14
WO2017072539A1 (en) 2017-05-04
PL3368683T3 (pl) 2020-07-27
SI3368683T1 (sl) 2020-07-31
HRP20200487T1 (hr) 2020-09-04
US20190085401A1 (en) 2019-03-21
EP3368683B1 (en) 2020-01-15
US20220073995A1 (en) 2022-03-10
DK3368683T3 (da) 2020-03-30
PT3368683T (pt) 2020-04-06
HUE048265T2 (hu) 2020-08-28
RS60075B1 (sr) 2020-05-29

Similar Documents

Publication Publication Date Title
CY1122871T1 (el) Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1
Ameling et al. Associations of circulating plasma microRNAs with age, body mass index and sex in a population-based study
Chen et al. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis
MX2020000604A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
Stark et al. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis
Foley et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis
Huang et al. HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
EA201792679A1 (ru) Способы диагностики и лечения злокачественной опухоли
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
JP2016513094A5 (el)
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
Lezhnina et al. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways
WO2015100459A3 (en) Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
Hu et al. Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer
WO2018183817A3 (en) Tumor burden as measured by cell free dna
Wang et al. MicroRNA-10b is upregulated and has an invasive role in colorectal cancer through enhanced Rhoc expression
Chi et al. Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics
JP2015210268A5 (el)
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
Lin et al. Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas
Song et al. Combined detection of HER2, Ki67, and GSTP1 genes on the diagnosis and prognosis of breast cancer
ZA201803854B (en) Biomarkers for prospective determination of risk for development of active tuberculosis
Yamagishi et al. Brain metastases in malignant pleural mesothelioma